Commercial/Healthcare Exchange PA Criteria

Effective: December 9th 2021

Prior Authorization: Qulipta™

Products Affected: Qulipta (atogepant) tablets

Medication Description: Migraine is a common, ongoing condition marked by paroxysmal, unilateral attacks of moderate to severe throbbing headache. Migraines are aggravated by routine physical activity (e.g., walking or climbing stairs) and associated with nausea, vomiting, and/or photophobia and phonophobia. Migraines have been defined as chronic or episodic. Chronic migraine is described by the International Headache Society as headache occurring on ≥ 15 days/month for more than 3 months, which has the features of migraine headache on ≥ 8 days/month. Episodic migraine is characterized by headaches that occur < 15 days/month. Qulipta, a calcitonin gene-related peptide (CGRP) receptor antagonist, is indicated for the preventive treatment of episodic migraine in adults.

Covered Uses: Qulipta is indicated for the preventive treatment of episodic migraine in adults.

Exclusion Criteria: Qulipta is contraindicated in patients currently using:

1. Injectable calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention **OR**
   In patients using Nurtec ODT (rimegepant orally disintegrating tablets**),** if Nurtec ODT is being taken for the preventative treatment of episodic migraine.
2. Acute treatment of migraine
3. Treatment of chronic or episodic cluster headache

Required Medical Information:

1. Diagnosis
2. Previous Medications tried and failed
3. Current Medications
4. Medical History

Age Restriction: 18 years of age and older

Prescriber Restriction: None

Coverage Duration: 12 months

Other Criteria:

I. Initial Approval Criteria:

1. Preventive Treatment of Episodic Migraine. Approve for 12 months if the patient meets **ALL** the following:

A. Patient has ≥ 4 and < 15 migraine headache days per month (prior to initiating a migraine-preventive medication); **AND**

B. Patient has tried at least two standard prophylactic (preventive) pharmacologic therapies, each from a different pharmacologic class; **AND**

Note: Examples of standard prophylactic (preventive) pharmacologic therapies include angiotensin receptor blocker, angiotensin converting enzyme inhibitor, anticonvulsant, beta-blocker, calcium channel blocker, tricyclic antidepressant, other antidepressant.

C. Patient meets **ONE** of the following criteria (i, ii, **or** iii):
   - **i.** Patient has had inadequate efficacy to both of those standard prophylactic (preventive) pharmacologic therapies, according to the prescriber; **OR**
   - **ii.** Patient has experienced adverse event(s) severe enough to warrant discontinuation of both of those standard prophylactic (preventive) pharmacologic therapies, according to the prescriber; **OR**
   - **iii.** Patient has had inadequate efficacy to one standard prophylactic (preventive) pharmacologic therapy and has experienced adverse event(s) severe enough to warrant discontinuation of another standard prophylactic (preventive) pharmacologic therapy, according to the prescriber; **AND**

D. Patient meets **ONE** of the following (i **or** ii):
   - **i.** Patient is NOT taking Qulipta and meets **ONE** of the following (a **or** b):
     - **a.** Patient has tried at least one triptan therapy; **OR**
     - **b.** Patient has a contraindication to triptan(s) according to the prescriber; **OR**

       Note: Examples of contraindications to triptans include a history of coronary artery disease; cardiac accessory conduction pathway disorders; history of stroke, transient ischemic attack, or hemiplegic or basilar migraine; peripheral vascular disease; ischemic bowel disease; uncontrolled hypertension; or severe hepatic impairment.
   - **ii.** Patient is currently taking Qulipta and has had a significant clinical benefit from the medication as determined by the prescriber.

     Note: Examples of significant clinical benefit include a reduction in the overall number of migraine days per month or a reduction in number of severe migraine days per month from the time that Qulipta was initiated.

Quantity Limit of 30 tablets for 30 days

References:

1. Qulipta™ tablets [prescribing information]. Madison, NJ: AbbVie; September 2021.
2. MacGregor EA. In the clinic. Migraine. *Ann Intern Med*. 2017;166(7):ITC49-ITC64.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	12/9/2021